This study aims to evaluate whether tranexamic acid (TXA), a medication that helps reduce bleeding, can decrease fluid drainage after breast reduction surgery. Participants will be randomly assigned to receive either intravenous TXA or no TXA during surgery. Additionally, one breast will receive TXA through the surgical drain, while the other will receive saline. This approach allows to compare the effects of TXA on fluid buildup and healing. The goal is to improve recovery and reduce complications after breast reduction surgery.
This single-center, prospective, randomized controlled trial investigates the effect of tranexamic acid (TXA) on postoperative drain output and recovery following bilateral reduction mammaplasty. While TXA is widely utilized to minimize intraoperative blood loss, its role in optimizing postoperative wound healing and fluid management in plastic surgery remains underexplored. Participants undergoing bilateral breast reduction will be randomized to receive either intravenous TXA or no TXA at the time of surgery. In addition, each breast will be independently randomized to receive TXA or saline via the closed-suction drain after skin closure. This split-body design enables a controlled intra-individual comparison of local TXA effects, while concurrently assessing systemic administration in a parallel fashion. Primary outcomes include total drain output per breast and time to drain removal. Secondary endpoints include the incidence of postoperative hematoma and patient reported outcomes. All outcome measures will be recorded using standardized protocols and assessed by blinded evaluators where applicable. Participants will be followed until 30 days postoperatively. Given the established safety profile of TXA and the relatively low-risk nature of the intervention, no independent data monitoring committee has been appointed. The study has been approved by the local IRB and will adhere to institutional standards for adverse event monitoring and reporting.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
160
Patients randomized to the IV TXA group will receive intravenous Tranexamic acid during the procedure. The dose will be 1g IV infused over approx. 10 minutes prior to skin closure (dosing of approx. 15 mg/kg, capped at 1 g, which is within safe limits).
Before wound closure, one 15mm round Jackson-Pratt (JP) drain is placed in each breast pocket, exiting through a lateral chest wall stab incision. The randomized topical TXA intervention is then applied through the drain into the breast after skin closure. The drains will then be temporarily clamped for 20 minutes to allow the TXA to dwell in the tissue and exert local effect. After this the clamp is released, the excess fluid sucked off and the drain connected to a drainage bottle.
Before wound closure, one 15mm round Jackson-Pratt (JP) drain is placed in each breast pocket, exiting through a lateral chest wall stab incision. The randomized saline intervention is then applied through the drain into the breast after skin closure. The drains will then be temporarily clamped for 20 minutes to allow the saline to dwell in the tissue and exert local effect. After this the clamp is released, the excess fluid sucked off and the drain connected to a drainage bottle.
Massachusetts General Hospital
Boston, Massachusetts, United States
RECRUITINGTotal drain output per breast per 24 hours post-surgery (mL) until drain removal
Drain outputs will be recorded separately for each breast twice daily until removal.
Time frame: From date of operation until drain removal up to 4 weeks.
Time to drain removal (days)
Drains will be removed per standard protocol by trained staff if the output is ≤30 mL in a 24-hour period for two consecutive days. The time to drain removal will be recorded.
Time frame: From date of operation until drain removal up to 4 weeks.
Change in drain fluid color from bloody to serous until drain removal assessed by daily observation
Qualitative change in drain fluid from bloody to serous. Measured by daily observation by clinical staff until drain removal. Change will be recorded as transition from bloody to serous.
Time frame: From postoperative Day 1 until drain removal, up to 4 weeks after surgery
Seroma Rate
Rate of clinically evident seromas in the postoperative follow-up period. Diagnosis will be based on physical examination and/or ultrasound when clinically indicated.
Time frame: From date of surgery until end of study (30 days postoperative).
Infection Rate
Rate of surgical site infections (superficial or deep) diagnosed based on CDC criteria during the postoperative period.
Time frame: From date of surgery until end of study (30 days postoperative).
Hematoma Rate
Rate of postoperative hematoma formation. Diagnosis will be based on physical examination and/or via imaging, if clinically indicated.
Time frame: From date of surgery until end of study (30 days postoperative).
Wound Dehiscence Rate
Rate of postoperative wound dehiscence identified clinically, including any spontaneous reopening of the surgical incision.
Time frame: From date of surgery until end of study (30 days postoperative).
Length of Hospital Stay
Duration of inpatient stay postoperatively, measured in days from the date of surgery to the date of discharge.
Time frame: From date of surgery until discharge from the hospital up to 4 weeks.
30-Day Readmission Rate
Rate of patients readmitted to the hospital within 30 days of the index surgery, regardless of cause.
Time frame: From date of surgery until end of study (30 days postoperative)
30-Day Revision Rate
Rate of reoperation or revision procedures performed within 30 days postoperatively due to complications.
Time frame: From date of surgery until end of study (30 days postoperative).
Patient-Reported Outcomes (BREAST-Q Breast Reduction Module)
The BREAST-Q Breast Reduction Module is a validated patient-reported outcome measure assessing satisfaction and quality of life following breast reduction surgery. Each subscale is scored from 0 to 100, with higher scores indicating greater satisfaction and/or better quality of life.
Time frame: Preoperative before surgery, 7 days after and 30 days after surgery.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.